Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Hawro, Tomasz ^a   Bogucki, Andrzej ^b   Krupińska Kun, Maria ^b   Maurer, Marcus ^a   Woźniacka, Anna ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; PHOSPHOLIPID ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BRAIN ISCHEMIA; CAUCASIAN; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CRITERION VARIABLE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HEADACHE; HUMAN; INTRACTABLE HEADACHE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PARTIAL THROMBOPLASTIN TIME; PREVALENCE; PROTEIN BINDING; SEIZURE; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CEREBROVASCULAR ACCIDENT; COMPLICATION; HEADACHE AND FACIAL PAIN; IMMUNOLOGY; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MIDDLE AGED; ODDS RATIO;

ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; FEMALE; HEADACHE DISORDERS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MIDDLE AGED; ODDS RATIO; SEIZURES; STROKE;

EID: 84925003453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119911     Document Type: Article

References (66)

1. Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 1992; 19(1):47-52.
2. Mevorach D, Elkon KB. Neuropsychiatric lupus: getting beyond the barrier of the brain. Lupus 1996; 5(3):173-174.
3. Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med. 1996; 156:1337-1344. PMID: 8651844
4. Harris EN, Gharavi AE, Asherson RA, Boey ML, Hughes GR. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol. 1984; 2:47-51. PMID: 6442638
5. Asherson RA, Khamashta MA, Gil A, Vazquez JJ, Chan O, Baguley E, et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med. 1989; 86:391-399. PMID: 2494884
6. Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus. 1999; 8:127-133. PMID: 10192507
7. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990; 335:1544-1547. PMID: 1972485
8. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64:2677-2686. doi: 10.1002/art.34473 PMID: 22553077
9. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4:295-306. PMID: 16420554
10. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40:1725. PMID: 9324033
11. Liang MH, Socher SA, Roberts WN, Esdaile JM. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum. 1988; 31:817-825. PMID: 3293570
12. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999; 42:599-608. PMID: 10211873
13. nd edition. Cephalalgia. 2004; 24 Suppl 1:9-160. PMID: 14979299
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198. PMID: 1202204
15. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997; 40:1601-1611. PMID: 9324014
16. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995; 74:1185-1190. PMID: 8560433
17. Tincani A, Allegri F, Balestrieri G, Reber G, Sanmarco M, Meroni P, et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res. 2004; 114:553-558. PMID: 15507291
18. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001; 57:496-500. PMID: 11502919
19. Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology. 2002; 58:1214-1220. PMID: 11971089
20. Afeltra A, Garzia P, Mitterhofer AP, Vadacca M, Galluzzo S, Del Porto F, et al. Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology. 2003; 61:108-110. PMID: 12847168
21. Robert M, Sunitha R, Thulaseedharan NK. Neuropsychiatric manifestations systemic lupus erythematosus: a study from South India. Neurol India. 2006; 54:75-77. PMID: 16679649
22. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol. 2003; 30:985-992. PMID: 12734893
23. Unterman A, Nolte JE, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011; 41:1-11. doi: 10.1016/j.semarthrit.2010.08.001 PMID: 20965549
24. Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007; 56:265-273. PMID: 17195230
25. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Clarke A, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011; 70:1726-1732. doi: 10.1136/ard.2010.148502 PMID: 21893582
26. Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsanoja R, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum. 2001; 45:419-423. PMID: 11642640
27. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore). 1976; 55:323-339. PMID: 781466
28. Hawro T, Bogucki A, Sysa-Jedrzejowska A, Bogaczewicz J, Wozniacka A. [Neurological disorders in systemic lupus erythematosus patients]. Pol Merkur Lekarski. 2009; 26:43-48. PMID: 19391506
29. Chiewthanakul P, Sawanyawisuth K, Foocharoen C, Tiamkao S. Clinical features and predictive factors in neuropsychiatric lupus. Asian Pac J Allergy Immunol. 2012; 30:55-60. PMID: 22523908
30. Singh S, Gupta MK, Ahluwalia J, Singh P, Malhi P. Neuropsychiatric manifestations and antiphospholipid antibodies in pediatric onset lupus: 14 years of experience from a tertiary center of North India. Rheumatol Int. 2009; 29:1455-1461. doi: 10.1007/s00296-009-0887-6 PMID: 19306097
31. Willis R, Pierangeli SS. Anti-beta2-glycoprotein I antibodies. Ann N Y Acad Sci. 2013; 1285:44-58. doi: 10.1111/nyas.12080 PMID: 23692565
32. Sciascia S, Bertolaccini ML, Roccatello D, Khamashta MA, Sanna G. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review. J Neurol. 2014; 261:1706-1714. doi: 10.1007/s00415-014-7406-8 PMID: 24952022
33. Hanly JG, Urowitz MB, Su L, Gordon C, Bae SC, Sanchez-Guerrero J, et al. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis. 2012; 71:1502-1509. doi: 10.1136/annrheumdis-2011-201089 PMID: 22492779
34. Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC, et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum. 2008; 58:843-853. doi: 10.1002/art.23218 PMID: 18311802
35. Kozora E, Filley CM, Zhang L, Brown MS, Miller DE, Arciniegas DB, et al. Immune function and brain abnormalities in patients with systemic lupus erythematosus without overt neuropsychiatric manifestations. Lupus. 2012; 21:402-411. doi: 10.1177/0961203311429116 PMID: 22170761
36. Hanly JG, Urowitz MB, O'Keeffe AG, Gordon C, Bae SC, Sanchez-Guerrero J, et al. Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum. 2013; 65:2887-2897. doi: 10.1002/art.38106 PMID: 24166793
37. Avcin T, Benseler SM, Tyrrell PN, Cucnik S, Silverman ED. A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum. 2008; 59:206-213. doi: 10.1002/art.23334 PMID: 18240179
38. Mitsikostas DD, Sfikakis PP, Goadsby PJ. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain 2004; 127:1200-1209. PMID: 15047589
39. Rasmussen BK. Epidemiology of headache. Cephalalgia. 2001; 21:774-777. PMID: 11595011
40. Sfikakis PP, Mitsikostas DD, Manoussakis MN, Foukaneli D, Moutsopoulos HM. Headache in systemic lupus erythematosus: a controlled study. Br J Rheumatol. 1998; 37:300-303. PMID: 9566671
41. Fernandez-Nebro A, Palacios-Munoz R, Gordillo J, Abarca-Costalago M, De Haro-Liger M, Rodriguez-Andreu J, et al. Chronic or recurrent headache in patients with systemic lupus erythematosus: a case control study. Lupus. 1999; 8):151-156. PMID: 10192510
42. Amit M, Molad Y, Levy O, Wysenbeek AJ. Headache in systemic lupus erythematosus and its relation to other disease manifestations. Clin Exp Rheumatol. 1999; 17:467-470. PMID: 10464560
43. Cavestro C, Micca G, Molinari F, Bazzan M, C DIP, Aloi R, et al. Migraineurs show a high prevalence of antiphospholipid antibodies. J Thromb Haemost. 2011; 9:1350-1354. doi: 10.1111/j.1538-7836.2011.04348.x PMID: 21585648
44. Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford). 2003; 42:200-213. PMID: 12595612
45. Tietjen GE, Day M, Norris L, Aurora S, Halvorsen A, Schultz LR, et al. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study. Neurology. 1998; 50:1433-1440. PMID: 9596001
46. Markus HS, Hopkinson N. Migraine and headache in systemic lupus erythematosus and their relationship with antibodies against phospholipids. J Neurol. 1992; 239:39-42. PMID: 1541968
47. Montalban J, Cervera R, Font J, Ordi J, Vianna J, Haga HJ, et al. Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus. Neurology. 1992; 42:681-682. PMID: 1549239
48. Cuadrado MJ, Khamashta MA, D'Cruz D, Hughes GR. Migraine in Hughes syndrome - heparin as a therapeutic trial? QJM. 2001; 94:114-115. PMID: 11181989
49. Mok CC, Lau CS, Wong RW. Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus. J Rheumatol. 2001; 28:766-771. PMID: 11327248
50. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology (Oxford). 2004; 43:1555-1560. PMID: 15342927
51. Sabbadini MG, Manfredi AA, Bozzolo E, Ferrario L, Rugarli C, Scorza R, et al. Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus. 1999; 8:11-19. PMID: 10025594
52. von Scheven E, Glidden DV, Elder ME. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum. 2002; 47:414-420. PMID: 12209489
53. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002; 46:1019-1027. PMID: 11953980
54. Sastre-Garriga J, Montalban X. APS and the brain. Lupus. 2003; 12:877-882. PMID: 14714905
55. de Carvalho JF, Pasoto SG, Appenzeller S. Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke. Clin Dev Immunol. 2012; 2012:981519. doi: 10.1155/2012/981519 PMID: 22489254
56. Peltola JT, Haapala A, Isojarvi JI, Auvinen A, Palmio J, Latvala K, et al. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. Am J Med. 2000; 109:712-717. PMID: 11137486
57. Verrot D, San-Marco M, Dravet C, Genton P, Disdier P, Bolla G, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med. 1997; 103:33-37. PMID: 9236483
58. Lakos G, Kiss E, Regeczy N, Tarjan P, Soltesz P, Zeher M, et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol. 1999; 117:574-579. PMID: 10469065
59. Mikdashi J, Krumholz A, Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology. 2005; 64:2102-2107. PMID: 15985581
60. Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GR. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum. 1994; 37: 568-571. PMID: 8147935
61. Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV, Garmendia M, Gabriel Erdozain J, Villar I, et al. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus. 2007; 16:810-816. PMID: 17895304
62. th International Congress on Antiphospholipid Antibodies. Arthritis Rheum. 2012; 64:1-10. doi: 10.1002/art.33349 PMID: 21953634
63. th International Congress on Antiphospholipid Antibodies. Clin Chim Acta. 2012; 413:358-360. doi: 10.1016/j.cca.2011.09.048 PMID: 22019907
64. Tincani A, Filippini M, Scarsi M, Galli M, Meroni PL. European attempts for the standardisation of the antiphospholipid antibodies. Lupus. 2009; 18:913-919. doi: 10.1177/0961203309106919 PMID: 19671792
65. Avcin T, Cimaz R, Meroni PL. Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations. Lupus. 2002; 11:4-10. PMID: 11898917
66. Piette JC, Cacoub P. Antiphospholipid syndrome in the elderly: caution. Circulation. 1998; 97:2195-2196. PMID: 9631867